Lantheus files Schedule 13D showing 20.9% stake in Radiopharm Theranostics
Lantheus Holdings disclosed a 20.9% beneficial stake in Radiopharm Theranostics Limited in a Schedule 13D filed September 4, 2026, with shares and options accumulated across 2024 and 2025.
Lantheus Holdings, Inc. disclosed a 20.9% beneficial stake in Radiopharm Theranostics Limited.
The position reflects shares and options accumulated across 2024 and 2025, according to the Schedule 13D filed on September 4, 2026.
The investment ties to a broader deal that includes asset transfers and…